Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung

Trial Profile

Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Nintedanib (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms VARGADO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Apr 2017 Planned End Date changed from 1 Dec 2020 to 31 Dec 2020.
    • 28 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 31 Dec 2020.
    • 19 Jul 2016 Planned End Date changed from 1 Mar 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top